🔬🧬 Hematology Updates: Kamada FDA Approval, ITP Trial Success, AI in Hemophilia and More
From the FDA greenlighting one of the largest plasma centers in the U.S. to gene editing milestones in sickle cell disease, and AI-enhanced care in hemophilia—this week’s hematology roundup covers the clinical and regulatory shifts reshaping blood disorder therapies.
💡 Key Highlights This Week:
✅ Kamada’s plasma center in Houston approved by FDA; capacity of 50,000 liters/year, projected revenue $8–10M
✅ Novartis hits Phase III goal in ITP with ianalumab + eltrombopag combo; supports future filings including VAYHIT1
🧠 GT Biopharma’s GTB-3650 advances to Cohort 3 in NK cell therapy trial after safety clearance; data expected late 2025
🧬 ImmunityBio’s CD19 CAR-NK shows complete responses and 6-month remission with rituximab in Waldenstrom’s
🧪 CIT Therapeutics raises $2.5M for SUMO E1 inhibitor SB-4826, set to enter Phase 1/1b for follicular lymphoma
🧬 BEAM-101 receives RMAT status from FDA; shows increased fetal hemoglobin and reduced sickle hemoglobin in 17 patients
📉 Pfizer’s inclacumab fails Phase III trial for VOC reduction; osivelotor also impacted by partial FDA hold
💉 Adynovate shows strong bleeding control in hemophilia A; 76.1% of South Korean patients had zero bleeds on prophylaxis
🤖 AI tools improve joint imaging and bleeding risk management in hemophilia; experts caution against premature adoption
🧲 Plasma metals including arsenic and vanadium linked to increased anemia risk in aging adults; protective effect seen with selenium and rubidium
🎯 Whether you’re following CAR-NK cell therapies, gene-editing breakthroughs, or bleeding disorder innovations—this episode covers the cutting-edge of hematology research and treatment evolution.
📢 Stay Ahead in Hematology Research!
✅ Like, share, and subscribe for weekly updates on hematologic diseases, biotech advances, and clinical trials
#Hematology #BloodDisorders #SickleCellDisease #GeneTherapy #CAR_NK #Hemophilia #ITP #BiotechNews #ClinicalTrials #PlasmaTherapies #AIinMedicine #LucidQuest #RMAT #HealthcareInnovation #Immunotherapy #PharmaUpdates #AnemiaResearch #FDAApproval #LucidQuestInsights #HematologyUpdates